Sinopharm Holding and Novartis Forge Deep Strategic Collaboration to Open a New Chapter in Oncology

On January 22, Sinopharm Group and Novartis China held a deep strategic cooperation signing ceremony. Lian Wanyong, President of Sinopharm Group, and Liu Tianyao, General Manager of the Global Procurement and Supply Chain Service Center; Li Yao, President and Managing Director of Novartis China, Yan Wei, Head of the Oncology Therapeutic Area, and Chen Hui, Head of Retail, Emerging Markets and the Commercial Department, attended and witnessed the signing ceremony.

Lian Wanyong expressed gratitude for the long-term support and trust that Novartis has given to Sinopharm Group. He noted that, looking back at history, the cooperation between Sinopharm Group and Novartis has been highly fruitful, especially in the field of oncology treatment, from the initial product introduction to market promotion, each step has witnessed the depth and breadth of the collaboration between the two parties. He emphasized that both sides should continue to deepen their cooperation on the existing basis and explore more new models and areas of collaboration.

Li Yao stated that through this visit, Novartis gained a deeper understanding of Sinopharm Group's comprehensive and diversified business model, further solidifying the strategic cooperation direction between Novartis and Sinopharm Group in the future. He pointed out that Novartis China is committed to becoming the most valuable and trustworthy healthcare partner in China. Hoping to leverage Sinopharm Group’s channel advantages, Novartis aims to accelerate the availability of innovative drugs in the Chinese market, benefiting a wider population of patients across China.

At the signing ceremony, the two parties had in-depth exchanges on deepening strategic cooperation and promoting the development of the pharmaceuticals industry. They also discussed enhancing the accessibility and affordability of drugs in the core field of cancer treatment in the future, as well as further expanding cooperation opportunities. Both parties agreed that, taking this strategic cooperation agreement as an opportunity, they would broaden the scope of collaboration in areas such as product introduction, specialty drug retailing, omni-channel marketing, and innovative payment solutions. They aim to continuously strengthen their strategic partnership to achieve mutual benefits and win-win results. While embarking on a new chapter of cooperation, they will contribute to the high-quality development of China's healthcare industry.